Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
WENZHOU, ZHEJIANG, CHINA, January 5, 2026 /EINPresswire.com/ — In the world of electrical engineering, automation, and power management, the relay is the quiet workhorse. It’s the component ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback